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Abstract
Background
Dengue, a mosquito-borne viral disease, poses a significant global public health risk. In
tropical countries such as India where periodic dengue outbreaks can be correlated to the
high prevalence of the mosquito vector, circulation of all four dengue viruses (DENVs) and
the high population density, a drug for dengue is being increasingly recognized as an unmet
public health need.
Methodology/Principal findings
Using the knowledge of traditional Indian medicine, Ayurveda, we developed a systematic
bioassay-guided screening approach to explore the indigenous herbal bio-resource to iden-
tify plants with pan-DENV inhibitory activity. Our results show that the alcoholic extract of
Cissampelos pariera Linn (Cipa extract) was a potent inhibitor of all four DENVs in cell-
based assays, assessed in terms of viral NS1 antigen secretion using ELISA, as well as
viral replication, based on plaque assays. Virus yield reduction assays showed that Cipa
extract could decrease viral titers by an order of magnitude. The extract conferred statisti-
cally significant protection against DENV infection using the AG129 mouse model. A prelim-
inary evaluation of the clinical relevance of Cipa extract showed that it had no adverse
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effects on platelet counts and RBC viability. In addition to inherent antipyretic activity in Wis-
tar rats, it possessed the ability to down-regulate the production of TNF-α, a cytokine impli-
cated in severe dengue disease. Importantly, it showed no evidence of toxicity in Wistar
rats, when administered at doses as high as 2g/Kg body weight for up to 1 week.
Conclusions/Significance
Our findings above, taken in the context of the human safety of Cipa, based on its use in
Indian traditional medicine, warrant further work to explore Cipa as a source for the develop-
ment of an inexpensive herbal formulation for dengue therapy. This may be of practical rele-
vance to a dengue-endemic resource-poor country such as India.
Author Summary
India represents ~50% of the global population estimated to be at risk of dengue. Severe
dengue, which is potentially fatal, correlates with very high virus load, reduction in platelet
counts and haemorrhage. Antiviral therapy to reduce high virus load may be beneficial in
attenuating disease severity. We have explored Indian traditional medicine, Ayurveda, to
identify plants that could be a source of dengue inhibitory activity. We show that an alco-
holic extract prepared from Cissampelos pareira Linn inhibited the replication of dengue
viruses in living cells in culture and protected mice against dengue infection. It also
showed antipyretic and anti-inflammatory effects. Importantly, this extract did not show
any toxic effects in rats and did not affect platelets and red blood cells. This observation is
critical as dengue fever is commonly treated with antipyretics. In a dengue-endemic
resource-poor country as India, the C. pareira plant may serve as a source for the develop-
ment of an inexpensive herbal formulation against dengue.
Introduction
Dengue disease is a major public health concern around the world. It is spread to humans
through the bite of Aedesmosquitoes which serve as carriers of the disease-causing viruses.
There are four serotypes of dengue viruses (DENV-1, -2, -3 and -4), belonging to the family
Flaviviridae [1], which are prevalent in more than a hundred mosquito-infested countries in
the tropical and sub-tropical regions of the globe [2, 3]. According to recent estimates, there
are annually ~400 million infections around the world and a fourth of these are associated with
symptomatic dengue illness [3]. Symptomatic dengue illness can range from mild dengue fever
(DF) to severe and potentially fatal dengue haemorrhagic fever (DHF) and dengue shock syn-
drome (DSS) [4]. In DF, the appearance of virus in the serum coincides with fever onset, with
titers reaching 106 infectious units/ml, at the peak of the febrile phase. In DHF/DSS patients,
the viremia can escalate by 1–2 logs [5, 6]. This is accompanied by potentially fatal manifesta-
tions of thrombocytopenia, haemorrhage, vascular leakage and shock [1, 2, 7]. Unless hospital-
ized and given supportive care and fluid replacement, DHF/DSS can be associated with high
case fatality rates [4]. Controlling the spread of dengue continues to be an intractable problem
due to the inability to eradicate the vector mosquitoes and the lack of safe, potent preventive
vaccine [8, 9]. Despite numerous hurdles, persistent efforts over the years have resulted in the
development of several live attenuated dengue vaccine candidates [9], one of which has
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undergone phase III clinical testing [10–12] and is expected to be licensed in the near future.
The challenges being faced in dengue vaccine development [13] have emphasized the need for
antiviral drugs and spurred new efforts in this direction [14–16].
In regard to drugs, a majority used in treating human illness [17] and several in clinical
development [18] can be traced to natural origins. India has a rich herbal repertoire which is
used in traditional ethnomedicine. The current work was undertaken with the objective of
exploring the possibility of identifying anti-DENV activity that may be associated with indige-
nous plants in India. To choose plants likely to provide useful leads, the study utilized knowl-
edge from traditional Indian medicine, Ayurveda, a specific branch of Indian ethnomedicine
[19]. Ayurveda prescribes medicines based on various herbs for a variety of illnesses. Though
dengue as such is not described in Ayurvedic literature, there are illnesses identified by symp-
toms that can be correlated with some of the clinical manifestations of dengue disease. Plants
shortlisted on this basis from the vast indigenous herbal bio-resource available in India were
screened for anti-DENV activity. This work describes the screening assays that were set-up to
identify anti-DENV activity and presents data identifying two plants that manifested inhibitory
potency against all 4 DENVs. One of these, chosen for further study to assess its in vivo efficacy
and clinical relevance, was found to be a promising candidate for further development as a
pan-DENV inhibitory formulation.
Methods
Cells and viruses
The mosquito cell line C6/36, the monkey kidney cell lines LLCMK2 and Vero, and human
hepatoma cell line HepG2 were from American Type Culture Collection, Virginia, U.S.A. C6/
36 cells were maintained in Leibovitz L-15 medium supplemented with 0.03% tryptose phos-
phate broth and 10% heat-inactivated fetal calf serum (ΔFCS) in a CO2-free incubator at 28°C.
The monkey kidney cells were maintained in Dulbecco’s Modified Eagle medium (DMEM),
supplemented with 10% ΔFCS, in a 5% CO2 humidified incubator, at 37°C. For HepG2 cells,
DMEM was replaced by Roswell Park Memorial Institute (RPMI) medium. The remaining
conditions were the same. Representatives of the four DENV serotypes (strain and accession
numbers are indicated in parentheses) used in this study were: DENV-1 (Nauru Island,
U88535); DENV-2 (New Guinea C, AF038403), DENV-3 (H87, M93130) and DENV-4 (Dom-
inica, M14931). These were propagated in C6/36 cells and titrated on LLCMK2 cells using a
standard plaque assay as described below.
Plants and preparation of extracts
Plants shortlisted for screening are indicated in Table 1. These were procured through local sup-
pliers and identified and authenticated by the resident herbal taxonomist at Ranbaxy Research
Laboratories, Gurgaon, India. Extracts were prepared using part(s) of the plants used in conven-
tional Ayurvedic preparations. In each case, three different extracts, methanolic, hydroalcoholic
and aqueous, were prepared using methanol, methanol: water (1:1), and water, respectively. Plant
parts were washed, shade-dried and pulverized prior to extraction. To prepare extracts, ~100 g
plant material was extracted three times with 500 ml extraction solvent at boiling point for 3
hours, each time. The three extractions were pooled, filtered and concentrated at low pressure
and temperature, and dried in a vacuum oven at room temperature (RT) for 16–18 hours. The
resultant material was dissolved in dimethylsulfoxide (DMSO), at 20mg/ml and stored at 4°C.
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Plaque assay
The titer of infectious DENV in virus stocks and in culture supernatants (in the type-3 screen-
ing assay, see below) were determined using a standard plaque assay as described previously
[20]. Briefly, LLCMK2 monolayers in 6 well plates were infected in duplicate with serial 10-fold
dilutions (prepared in DMEM+2%ΔFCS) of the virus-containing samples (250μl/well). Mock-
infections were performed in parallel using an equivalent volume of virus diluent alone. Two
hours later, the infected monolayers (after aspirating off the virus inoculum) were overlaid
with DMEM+6%ΔFCS containing 1% methyl cellulose (2 ml/well), and incubated for 6 days
(37°C, 5% CO2). On day 6 post-infection, the overlay was removed and the cells fixed with 4%
formaldehyde solution (1 ml/well). Fixed cells were washed and stained with 0.05% (w/v) crys-
tal violet solution in 20% ethanol. Revealed plaques were counted to determine the virus titre,
expressed as plaque-forming units (PFUs)/ml.
Cell-based bioassays for antiviral screening
The initial antiviral screening assay, designated as the type-1 assay, was based on the plaque
reduction neutralization test (PRNT) described earlier for determining DENV-neutralizing
antibody titres in sera [20]. LLCMK2 cells were seeded in 24-well plates (5x10
5 cells/well), a
day in advance. DENV-1, -2, -3 and -4 (100 PFU each) were separately pre-incubated with
serial dilutions of herbal extracts (corresponding to 0–100 μg/ml final concentration) in 300 μl
volume, at 4°C overnight. The pre-incubation mixture was diluted with an equal volume of
medium (DMEM+ 2% ΔFCS) and used to infect LLCMK2 cells (3 wells for each concentration
at 200 μl/well) in the 24-well plate. After 2 hours of adsorption in the incubator (37°C, 5%
Table 1. Screening of plant extracts for anti-DENV activity.
No. Name of Plant Part useda Antiviral Activityb
1 Aconitum heterophyllum Rhizome -
2 Andrographis paniculata Whole plant -
3 Azadirachta indica Bark -
4 Cedrus deodara Resin -
5 Cissampelos pareira Aerial part +
6 Coptis teeta Root +
7 Cyperus rotundus Rhizome -
8 Desmodium gangeticum Whole plant +
9 Enicostemma littorale Whole plant -
10 Fumaria indica Whole plant +
11 Ocimum sanctum Whole plant -
12 Phyllanthus amarus Whole plant +
13 Picrorhiza kurroa Rhizome ±
14 Premna mucronata Bark +
15 Swertia chirayata Whole plant -
16 Terminalia chebula Fruit +
17 Tinospora cordifolia Stem +
18 Aloe vera Leaf -
19 Citrullus colocynthis Root -
aMethanolic extracts were prepared using parts of the plant mentioned in Ayurvedic literature
bAntiviral activity against DENV-3 screened using Type-1 assay. “+” indicates active extract (IC50 <25μg/ml);
“±” indicates borderline extracts (IC50 = ~25μg/ml); “-” indicates inactive extract (IC50 >25μg/ml)
doi:10.1371/journal.pntd.0004255.t001
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CO2), infected cells were overlaid with methylcellulose-containing growth medium and pro-
cessed thereafter as described for the plaque assay above. To assess any potential cytotoxicity,
cells were exposed to the herbal extracts (in the same concentration range) in the absence of
DENV infection. Additional control experiments, run in parallel, included cells which were
either mock-infected (negative control) or infected with DENV in the absence of herbal extract
(positive control). The half-maximal inhibitory concentration (IC50 value) for each herbal
extract against each DENV serotype, with reference to the positive control which represented
100% infection (or 0% inhibition), was defined as the concentration of herbal extract, in μg/ml,
resulting in 50% inhibition of the plaque count.
In the type-2 screening assay, LLCMK2 cells in 24-well plates were infected with DENVs
(moi = 0.002) without pre-incubating with the herbal extracts. After 2 hours of adsorption, the
virus inoculum was aspirated, the monolayer rinsed, and then fed with complete medium con-
taining the herbal extracts (corresponding to 0–200 μg/ml final concentration). After 24 hours
of exposure to the extract, the monolayer was aspirated and overlaid with growth medium con-
taining methyl cellulose and plaques developed 6 days later as above.
The type-3 assay was done using Vero cells, as these cells secrete the viral antigen NS1 and
the infectious virions efficiently into the culture medium upon DENV infection. The assay
design was similar to the type-2 assay, except that following sequential exposure of cells to
DENV and herbal extract, cells were fed with liquid growth medium, instead of the methylcel-
lulose overlay. Aliquots of the culture supernatant were withdrawn at periodic intervals up to 9
days for estimation of NS1 antigen levels (using a commercial ELISA kit) and virus titres (by
plaque assay, as described above).
Determination of cytotoxicity of Cipa extract
Cytotoxicity was evaluated in two cell lines, LLCMK2 (in which the antiviral activity of the
extracts were assayed) and HepG2, a commonly used liver cell surrogate for in vitro cytotoxic-
ity testing. Cells seeded in 96-well plates were exposed to a wide concentration range of Cipa
extract (1–200 μg/ml) for 3 days. Cell viability was assessed using a commercial MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay kit (Sigma, cat. # M5655)
with reference to control cells that were not exposed to the extract. The half-maximal cytotoxic
concentration (CC50 value) for the herbal extract, with reference to the positive control
(untreated cells) which represented 100% cell viability (or 0% cytotoxicity), was defined as the
concentration of herbal extract, in μg/ml, resulting in 50% cytotoxicity. Selectivity index (SI) of
an extract is defined as the ratio of CC50 to IC50 values obtained using the LLCMK2 cell line.
Effect of pre-incubation time and virus dose on the anti-DENV activity of
Cipa extract
To assess if the duration of pre-incubation of the Cipa extract with DENV influenced antiviral
activity in the type-1 assay format, pre-incubation times ranging from 0–24 hours were tested
using ~50 PFUs of DENV-3.
To assess the effect of the size of the DENV dose on the anti-DENV efficacy of Cipa extract
in the pre-incubation step (at 4°C, overnight), type-1 assays were performed using DENV-3
ranging from 50 to 5000 PFUs. Each dose of DENV-3 was assayed against Cipa extract ranging
in concentration from 0–200 μg/ml.
Evaluation of in vivo efficacy of Cipa extract in the AG129 mouse model
To prepare a stock of challenge virus capable of lethal infection in AG129, we used a previously
published strategy [21, 22] with some modifications. Essentially DENV-2 (NGC) was
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alternately passaged between AG129 (intracranial inoculation of 106 PFU) and C6/36 cells in
tissue culture. After 4–5 such cycles of passaging, the virus was tested in AG129 mice to deter-
mine the minimum lethal dose (MLD) by i.p. injections. MLD is defined as the dose that can
cause clinical symptoms and 90–100% death 3–4 weeks post challenge. The challenge virus
stock thus obtained was titrated, aliquotted and stored in liquid N2 until use. To test protective
efficacy of Cipa extract, AG129 mice (9–12 weeks old, 20–24 g body weight) were challenged
with 106 PFU (per mouse, 0.4 ml, i.p) of the challenge DENV-2 stock described above. Chal-
lenged mice were divided into groups (n = 6) and treated orally with vehicle alone (0.25%
methyl cellulose) or with two different doses of Cipa extract (at 125 mg and 250 mg/kg body
weight). The methanol in the Cipa extracts administered to mice was removed completely by
evaporation. The resultant methanol-free Cipa paste was thoroughly re-suspended in 0.25%
methyl cellulose water and administered orally to infected mice. The volume of the oral dose
was adjusted in accordance with the body weight of each animal (10 ml/Kg/dose) and adminis-
tered by a trained veterinarian using a specially designed mouse feeder needle fitted with a
graduated 1 ml disposable syringe. The treatment was initiated 2 hours post-infection and con-
tinued twice daily for 5 consecutive days. Animals were monitored twice daily for a period of
35 days for clinical symptoms and mortality. A control (sham) group that was not virus-chal-
lenged, but which received Cipa extract (250 mg/kg), was also tested in parallel. At the end of
the experiment, the survival data was used to plot Kaplan Meier survival curves and analysed
by the log rank test (Mantel-Cox) test for statistical significance using GraphPad Prism 5
software.
Determination of effect of paracetamol on Cipa extract in vitro and in vivo
Interaction between paracetamol and Cipa extract was assessed in vitro using type-1 assay
format as follows. DENV-3 (~50 PFUs) and Cipa extract (ranging in concentration from
0–50 μg/ml) were pre-incubated overnight at 4°C in a volume of 100 μl, and used to infect
LLCMK2 cells in 24-well plates. Parallel infections were set up using pre-incubation mixtures
containing paracetamol (1–100 μg/ml), in addition to DENV and Cipa extract. As before,
mock-infections and DENV only infections (in the absence of Cipa and paracetamol) were also
set up and analysed in parallel.
The in vivo effect of Cipa extract in the presence and absence of paracetamol was assessed
using the Wistar rat pyrexia model. Wistar rats (weighing 180–220g) of either sex were used.
Basal temperature of the rats was measured using a digital rectal thermometer (Experimetria
Ltd., Hungary) and then injected subcutaneously (in the intra-scapular region) with 20% brew-
er’s yeast (10 ml/kg body weight) and allowed to fast overnight with free access to water. At 18
hours post-injection, rectal temperatures were recorded again to identify animals that regis-
tered0.7°C rise in body temperature for inclusion in the study. Groups (n = 7–9) of febrile
rats were orally administered paracetamol (200 mg/kg), or Cipa extract (200 mg/kg) or both.
Rats in the control group received just the vehicle (0.5% methyl cellulose). This was followed
by recording of rectal temperature for 3 hours at 30 minute intervals.
Effect of Cipa extract on erythrocytes and platelets ex vivo and in vivo
For ex vivo studies, human blood was collected from healthy adult donors after informed con-
sent. Erythrocytes were pelleted down in a centrifuge (1500xg, 5 minutes) from freshly col-
lected heparinized blood, rinsed thoroughly with PBS (pH 7.4), and used to make a 1% cell
suspension in PBS. Cipa extract ranging in concentration from 12.5 to 400 mg/L was added to
the erythrocyte suspension and incubated at 37°C for 1 hour. After this, the samples were spun
down, and the absorbance of the supernatant measured at 576 nm to determine the extent of
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erythrocyte lysis. Controls wherein erythrocytes were incubated with buffer alone (0% lysis),
DMSO alone (Cipa solvent) and 0.1% Triton X-100 (100% lysis) were processed in parallel.
Basal platelet count in freshly collected heparinized blood and in blood pre-incubated with
DMSO (vehicle) or Cipa extract (2–10 μg/ml) for different durations (1–4 hours) was deter-
mined using a Beckman Coulter hematology analyser.
For in vivo studies, four groups (n = 5) of Wistar rats were fasted overnight and adminis-
tered orally with vehicle (0.25% methyl cellulose) or Cipa extract, at three different dosages
(100, 300 and 1000 mg/kg body weight). Blood was collected just before Cipa extract adminis-
tration (0 hour) and at 1 and 4 hours post-administration. Hematology parameters were mea-
sured using ADVIA-120 hematology analyser.
Cytokine release assay
Human peripheral blood mononuclear cells (PBMCs) were obtained as follows. Freshly col-
lected heparinized blood was diluted with an equal amount of RPMI 1640 medium and lay-
ered on Ficoll Hypaque 1077 and centrifuged at 2,500 rpm for 25 minutes at RT. The upper
layer was discarded and the fluffy layer at the interphase was harvested, rinsed and re-sus-
pended in RPMI 1640 at 5x105 cells/ml. Freshly collected PBMCs were seeded in 96-well
plates (105 cells/well) and treated with Cipa extract at different dilutions (in RPMI 1640), fol-
lowed by 30 minutes incubation at RT on a rotary shaker (200 rpm). Next, wells were treated
with 50μl (4μg/ml) lipopolysaccharide (Sigma Cat. # L2654) and allowed to incubate for a
further 30 minutes at RT. The volume per well was made up to 200 μl using RPMI+10%FCS
and the plates incubated overnight at 37°C in a CO2 incubator. Negative controls (no lipo-
polysaccharide treatment) were run in parallel. The plates were centrifuged (3000 rpm,
10 minutes) to obtain clarified supernatants for TNF- α (e-Bioscience, cat # BMS223/4TEN,)
and IL-1β (BD Bioscience, cat # 557953) determinations using commercial ELISA kits as per
the vendors’ instructions.
Toxicology
Groups of 5 adult Wistar rats were orally administered 4 ml 0.25% methyl cellulose (vehicle)/kg
or 4 ml vehicle containing 400 mg to 2000mg Cipa extract/kg, once daily for 7 days (in accor-
dance with OECD guidelines- 407). During this period, food intake, body weight, and clinical
signs were monitored daily. At the end of the experiment, animals were euthanized, followed by
determination of hematological (Hb, WBC count, RBC count, platelet count and hematocrit)
and biochemical (SGOT, SGPT, total protein, serum albumin, total cholesterol, urea, creatinine
and random sugar) parameters. Necropsy was performed. Organ weights were recorded and his-
topathology was done.
Ethical clearance
Human blood from healthy volunteers was collected after written informed consent in strict
accordance with approved guidelines of the Human Ethics Committee, Ranbaxy Laboratories,
which approved the ‘Clinical protocol for collection of blood samples from healthy adult
human subjects for screening of potential new chemical entities to inhibit cytokine release and
other in vitro parameters in an assay system’ through Ethical Approval number: 5001_cok_11.
All animal experiments were performed in strict accordance with guidelines specified by the
Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA)
of the Government of India. Animal experimental protocols were approved by the Institutional
Animal Ethics Committee (IAEC) of Ranbaxy Research Laboratories, India through Approval
number 151/07.
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Results
Design of screening assays
Three bioassays were developed to identify herbal extracts with potential DENV-inhibitory
activity, as shown schematically in Fig 1. The type-1 assay was designed to identify herbal
extracts that had the ability to block DENV from entering susceptible cells. As a standardized
reference is not available to assess the efficacy of DENV inhibitory potency, PRNT data of
monoclonal antibodies (mAbs) were used to decide on the cut-off value in the type-1 assay. For
example, two pan-DENV mAbs, 4G2 and DB13-19, show half maximal inhibition of DENV-2
plaque counts at 11 and 33 μg/ml, respectively [23]. Based on this observation, an extract
which showed an IC50 value 25μg/ml, a value which falls between these two, was designated
to be active as a DENV inhibitor. Considering that this value is for a crude multicomponent
extract, it represents a stringent cut-off. In the context of antiviral screening, this assay had the
following possible outcomes: the extract could be cytotoxic (compromised monolayer), inactive
(no reduction in plaques in comparison to control infection), or active (reduced number of pla-
ques). However, the type-1assay is not likely to necessarily reveal if the active extracts also pos-
sessed the ability to inhibit post-entry steps in the DENV life cycle.
The type-2 assay was designed to assess the capacity of the herbal extracts to inhibit DENVs
within the cell. Therefore, DENV infection preceded exposure to the herbal extract. As the
herbal extract must be internalized before it exerts any inhibitory effect, we decided to use
higher amounts of the extract. Accordingly, the cut-off in the type-2 assay was increased to
150μg/ml. Possible outcomes in the type-2 assay are as follows: once again, the extract could be
Fig 1. Schematic representation of the antiviral screening assays. An outline of the three types of screening assays (indicated by Arabic numbers 1, 2
and 3) is shown. The multi-coloured sphere represents DENV and the Eppendorf tube with green liquid represents the herbal extract. These two were pre-
incubated (1) before addition to the monolayer or added sequentially (2, 3) to the monolayer. In assays 1 and 2, the treated-monolayers were overlaid with
methyl cellulose-containing growth medium. Shown at the bottom are the possible outcomes of the type 1 and 2 assays. The ‘x’mark denotes failure of entry
into cells. In assay 3, liquid growth medium was added instead of the methyl cellulose overlay, and followed by analysis of NS1 and virus released into the
culture supernatant.
doi:10.1371/journal.pntd.0004255.g001
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cytotoxic. If not, it may be ineffective due to one of two reasons: the extract failed to enter the
cells, or it was ineffective despite successful entry. The final possibility is that the extract would
reduce the plaque count, indicating antiviral activity. The type-3 assay was designed to monitor
inhibition based on reduction in viral antigen production and virus yields from DENV-infected
cells following treatment with herbal extracts. The amounts of viral NS1 antigen and infectious
virus released into the culture supernatant were measured over time to gauge the magnitude of
inhibition.
In order to identify an effective herbal extract against dengue, it was reasoned that it must
target all four DENVs. Further, it would be desirable to be able to inhibit the viruses both
before as well as after entry into susceptible cells. Towards this end, all extracts were screened
against a single DENV serotype in the type-1 assay, followed by screening of the active extracts
against the remaining three serotypes. Next, extracts manifesting pan-DENV inhibitory poten-
tial in the type-1 assay were progressed to screening in the type-2 assay. Extracts identified as
active against all 4 DENVs in the type-1 and -2 assays were tested in type-3 assay to assess their
ability to reduce virus titres by ten-fold.
Identification of plant extracts with pan-DENV inhibitory activity
Nineteen plants described in Ayurvedic literature as being beneficial in the treatment of ill-
nesses with dengue-like symptoms were shortlisted for bioassay guided screening (Table 1).
Initial screening showed that only the methanolic extracts manifested antiviral activity when
assayed against DENV-2 or DENV-3. The hydroalcoholic and aqueous extracts of all 19 plants
selected for the study did not manifest any antiviral activity when tested against these two
DENV serotypes (IC50>>100μg/ml). As a result, all subsequent studies were carried out using
the methanolic extracts.
Methanolic extracts were prepared from each of these and screened against DENV-3 in a
type-1 assay. Extracts that manifested IC50 values below the pre-designated cut-off were scored
as positive and the remaining as negative for antiviral potency. The results are summarized in
Table 1. This screening assay revealed 8 of 19 extracts to possess definite anti-DENV-3 inhibi-
tory activity, while one manifested borderline inhibition. These 9 extracts were then screened
against the remaining three DENV serotypes as well in the type-1 assay. These results, shown
in Table 2, revealed that 4 of the 9 anti-DENV-3 extracts manifested potent inhibitory activity
Table 2. Extracts with Pan-DENV inhibitory activity.
No. Extract Antiviral activity (IC50, μg/ml)
DENV-1a DENV-2 a DENV-3 a DENV-4 a DENV-3 b
1 Cissampelos pareira 11.11 1.97 3.17 1.23 78
2 Coptis teeta 11.11 5.04 7.87 33.33 >200
3 Desmodium gangeticum 12.5 6.7 14.62 12.5 >200
4 Fumaria indica 12.5 7.02 11.32 12.5 >200
5 Phyllanthus amarus 3.7 8.33 20.76 11.11 145
6 Picrorhiza kurroa 12.5 16.02 27.14 25 >200
7 Premna mucronata 12.5 27.9 21.37 12.5 >200
8 Terminalia chebula 25 70 11.2 50 >100
9 Tinospora cordifolia 50 58.75 16.02 25 >100
aType-1 assay (carried out using all DENV serotypes)
bType-2 assay (carried out using DENV-3 alone)
doi:10.1371/journal.pntd.0004255.t002
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against the remaining three DENV serotypes as well. The rest were effective at least against two
other DENV serotypes. When all these 9 were tested in a type-2 assay against DENV-3 to iden-
tify extracts that may inhibit the virus after its entry into cells, two extracts, one obtained from
Cissampelos pareira Linn, and the other from Phyllanthus amarus, were effective in curbing
DENV-3 (IC50 values<150 μg/ml). Extending the type-2 assay to DENV-1, -2 and -4 revealed
that both these extracts possessed the ability to inhibit all four DENVs even after their entry
into cells (Table 3). While Phyllanthus amarus has been documented to possess antiviral prop-
erties against another flavivirus, Hepatitis C virus [24] as well as many other viruses [25], this
is the first report of antiviral activity associated with Cissampelos pareira Linn. Further studies
in this work focused on Cissampelos pareira Linn, henceforth designated as Cipa for
convenience.
Cipa extracts from different geographical locations are similar in
composition and antiviral potency
From the perspective of evaluating the availability of starting material, it was considered neces-
sary to ascertain the extent of seasonal and geographical variations in the capacity of the Cipa
extract to manifest DENV inhibitory activity. To this end, extracts were prepared from Cipa
plants collected during different seasons from multiple geographical locations within India.
Analysis of these extracts revealed that the anti-DENV inhibitory activity is evident in plants
collected during the flowering season of April to September [26]. In the experiment, the results
of which are summarized in Table 4, Cipa extracts were prepared from plants obtained during
the flowering season from four different locations, and evaluated using the type-1 assay
described above. The data show that Cipa extracts manifested pan-DENV inhibitory activity in
both assay formats. Further, the observed mean pan-DENV IC50 values were not significantly
different for all four geographic locations tested. Fractionation of the methanolic extracts with
different solvents resulted in nominal increase in antiviral efficacy and a significant loss in
Table 3. Extracts displaying pan-DENV inhibitory activity in Type-2 assay.
No. Extract Antiviral activity (IC50, μg/ml)
DENV-1 DENV-2 DENV-3 DENV-4
1 Cissampelos pareira 100 125 78 100
2 Phyllanthus amarus 100 133 145 100
doi:10.1371/journal.pntd.0004255.t003
Table 4. Profile of anti-DENV activity of extracts fromCipa collected from geographically diverse locations.
Extract/Fraction S. India N. India Rajasthan M. P.
IC50
a (μg/ml) Yieldb (%) IC50
a (μg/ml) Yieldb (%) IC50
a (μg/ml) Yieldb (%) IC50
a (μg/ml) Yieldb (%)
Methanolic 7.12 6 8.01 5.96 7.46 8.62 21.38 13.2
Hexane 2.33 1.37 2.10 1.25 2.89 1.5 2.79 2.15
Chloroform 1.02 0.53 1.05 0.66 1.08 0.25 3.62 0.26
Dichloromethane 2.94 0.61 1.61 0.69 1.72 0.22 6.42 0.3
Ethyl acetate 2.89 2.57 4.07 2.74 2.7 2.93 4.65 3.44
Acetone 1.68 2.11 3.05 2.02 1.88 2.3 2.93 2.78
aDenotes pan-DENV inhibitory activity (mean of the IC50 values targeting each of the four DENV-serotypes)
b% Yield = (wt. of extract or fraction obtained/wt. of starting material) x100
doi:10.1371/journal.pntd.0004255.t004
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yield. Data in Table 4 show that among the solvents tested, methanol extraction is the best with
yields ranging from 6–13%. In addition, a preliminary LC-MS analysis of extracts from two dif-
ferent locations (S1 Fig), demonstrates that the two Cipa extracts manifest essentially similar
profiles. This leads to the conclusion that there is no discernible geographical variation and
that the method of extract preparation is standardized and reproducible.
Cipa extract inhibits secretion of viral antigen and infectious virus
The kinetics of virus inhibition by Cipa extract was analysed in a type-3 assay. Aliquots of the
culture supernatant were withdrawn at regular intervals over a period of several days and ana-
lysed for the presence of viral NS1 antigen and infectious virus, as shown in Fig 2. In control
experiments wherein infected cells were not exposed to Cipa extract, NS1 antigen was detect-
able after day 2 onwards and rising thereafter during the course of the experiment. In parallel
experiments, the exposure of cells to Cipa extract had a dose-dependent inhibitory effect on
NS1 antigen secretion. While the inhibition resulting from exposure to a low dose of Cipa
extract was manifested after day 4 post-infection, inhibition at higher doses was evident earlier
and at relatively higher magnitudes (Fig 2A). In fact, at the highest dose of Cipa extract tested
in this experiment (100μg/ml), the inhibition of NS1 antigen was near total for the entire dura-
tion of the experiment. The inhibition of viral antigen synthesis evident from this experiment
suggests that virus production would also be similarly affected. This notion was substantiated
by determination of viral titers in the culture supernatants during the course of the above
experiment, as shown in Fig 2B. In the control experiment, viral titers increased steadily reach-
ing a plateau at day 3 post-infection. Cipa extract lowered viral titers in a dose-dependent man-
ner as seen for NS1 secretion. Thus, at the lowest concentration of Cipa extract used, reduction
in viral titers became apparent from day 4 onward. Significantly, a small increase in the Cipa
dosage resulted in>1 log reduction in viral titer as early as day 3 post-infection. At the highest
dose of Cipa extract tested (100μg/ml), the drop in viral titers was ~2 logs. Importantly, the
reduction in viral titers was sustained over a period of several days. Interestingly, the magni-
tude of inhibition appeared to be greater based on NS1 levels compared to viral titers. The data
Fig 2. Inhibition of DENV antigen and virus production byCipa extract treatment. Vero cells were used to test the effect of Cipa extract on DENV-3 in a
type-3 assay format. The figure depicts the kinetics of NS1 antigen (A) and infectious virus (B) released into the culture supernatant in the absence (empty
black circles) and presence of Cipa extract at 22 μg/ml (filled blue circles), 66 μg/ml (empty red squares) and 200 μg/ml (filled green squares) concentrations.
doi:10.1371/journal.pntd.0004255.g002
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suggest that the Cipa extract may have effects on NS1 antigen synthesis and release that are dis-
tinct from its effects on virus replication.
Next, a complementary experiment was performed wherein DENV-3 was pre-incubated
with increasing concentrations of Cipa extract for different periods of time before infection
(type-1 assay) and overlay. Plaque counts obtained at the end of the experiment revealed a
dose- and time-dependent virucidal effect of Cipa extract on DENV-3 as depicted in Fig 3. A
converse experiment, again in type-1 format, was carried out to determine the inhibitory effi-
cacy of the extract against DENV-3 stocks whose titers varied over 2 logs. The IC50 values cor-
responding to DENV-3 dosage of 50, 500 and 5000 PFUs were, respectively, 9.92, 12.5 and
44.45 μg/ml. This leads to the conclusion that the antiviral potency of Cipa extract extends over
a wide range of viral loads.
Next, we tested Cipa extract for its efficacy in vivo. For this, we used the AG129 mouse
which has emerged in recent years as a promising dengue model [21, 27] for testing potential
DENV inhibitors [28]. This mouse is capable of hosting replication of brain-adapted DENV
administered intra-peritoneally (i.p.) and succumbs to it at high challenge doses [27]. We
developed a mouse brain-passaged DENV-2 (New Guinea C)-derived challenge strain [22]. At
a dose of 106 PFU (given i.p.), it was lethal to AG129 mice, killing them 25 days post-challenge.
The illness which preceded death was characterized by ruffled fur, lethargy, hunched back and
hind limb paralysis (S2 Fig). We found that the median survival time (MST) of challenged
mice treated orally with Cipa extract (methanol-free, see ‘Methods‘) twice a day for 5 days
post-challenge was increased in a dose-dependent manner. The survival data are present in
Fig 4. The MST of challenged mice was 19 days under the experimental conditions. At 125 mg
dose, given twice a day for 5 days, survival was 50% and MST was 28 days (p = 0.1). This
increased to ~67% when the dosage was doubled. Compared to the placebo-treated (0.25%
methyl cellulose) group, the level of protection afforded by 250 mg/Kg dose was statistically sig-
nificant (p = 0.021). It is to be ascertained in future if the protective efficacy may be further
enhanced by extending the drug treatment regimen beyond 5 days.
Clinical relevance of Cipa extract as a DENV antiviral
Since the data so far showed that Cipa extracts have potent pan-DENV inhibitory activity, it
was considered worthwhile to explore the feasibility of its therapeutic use. As DF is normally
treated with paracetamol, it would be important to ascertain the nature of any interaction
Fig 3. Effect of pre-incubation time on antiviral activity ofCipa extract.DENV-3 (50 PFU) was pre-
incubated with Cipa extract at 11 μg/ml (filled red circles), 33 μg/ml (empty blue squares) and 100 μg/ml (filled
black squares) for different durations (2–24 hours) followed by assay of antiviral activity in a type-1 assay.
doi:10.1371/journal.pntd.0004255.g003
Herbal Extract with Pan-Dengue Inhibitory Activity
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0004255 December 28, 2015 12 / 20
between Cipa and this drug. Dengue disease predisposes some patients to hemorrhagic mani-
festations and tends to be associated with lowered platelet counts. In this context, it also
becomes important to assess if Cipa would have any effect on RBCs and platelets. These con-
cerns were addressed in the following experiments. The data from the studies on Cipa extract
and paracetamol are depicted in Fig 5. A type-1 assay was carried out in which DENV-3 was
pre-incubated with serial dilutions of a Cipa extract. It was observed that DENV-3 infectivity
was inhibited progressively as the Cipa extract concentration increased, with an IC50 value of
6.1μg/ml. The addition of up to 100μg/ml paracetamol into the DENV-3/Cipa extract pre-incu-
bation mix did not significantly affect the inhibitory profile of Cipa. The calculated IC50 values
in the presence of paracetamol at 1, 10 and 100μg/ml were, respectively, 8.4, 7.4 and 8.5μg/ml
(Fig 5A). Paracetamol by itself at all concentrations tested did not have any effect on DENV
infectivity (plaque counts obtained with DENV-3 alone and DENV-3 plus paracetamol at
100μg/ml were, 43±3 and 45±4, respectively; n = 3). The next experiment examined the effect
of Cipa extract on the antipyretic activity of paracetamol using the Wistar rat pyrexia model.
Interestingly, this experiment revealed that Cipa extract possessed intrinsic antipyretic effect
(Fig 5B). When rats, in which fever was induced by subcutaneous injection of brewer’s yeast,
were treated with Cipa extract, the fever was suppressed at an efficiency that was comparable to
that of paracetamol. Interestingly, co-administration of Cipa extract with paracetamol had a
synergistic effect, resulting in a more pronounced decrease in body temperature.
In the next set of experiments, whole blood from human volunteers was collected and plate-
lets counts obtained before and after 1–4 hours post-mixing with Cipa extract. The results are
shown in Fig 6A. In the control sample, blood mixed with vehicle (saline), platelet counts
declined steadily over time. Cipa extract-treated blood samples manifested no statistically
Fig 4. Evaluation of protective efficacy of Cipa extract in vivo. AG129 mice (9–12 weeks old) were
injected i.p. with 106 PFU brain-passaged DENV-2. Infected mice were treated orally with 0.25%methyl
cellulose (solid red squares) or Cipa extract at 125 mg (empty blue circles) and 250 mg/kg body weight (solid
blue circles). Treatment was twice daily for the first 5 days. A sham control group that was not virus-infected,
but which received the higher dose of Cipa extract orally (solid green squares), was tested in parallel. The
mice were monitored daily for mortality and the resultant data plotted as Kaplan-Meier survival curves. The
p values to assess the statistical significance in the survival rates on day 35 between the Cipa extract-treated
and placebo-treated (0.25%methyl cellulose) groups were determined using the Log-rank test.
doi:10.1371/journal.pntd.0004255.g004
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significant change in platelet counts with respect to their cognate controls, up to 2 hours
(p>0.05). At four hours, the Cipa extract-treated samples displayed significantly higher
(p<0.05) platelet counts, compared to corresponding saline-treated control. The apparent
platelet-protective effect of Cipa extract is intriguing and merits further investigation. Essen-
tially similar results were observed at 2 and 10 μg/ml Cipa extract concentrations, indicating
that Cipa extract did not affect platelets adversely. The effect of Cipa extract on platelets was
Fig 5. Analysis of interaction between paracetamol andCipa extract. (A) DENV-3 (50 PFU) was pre-incubated with Cipa extract in the absence (solid
black diamonds) or presence of 1 μg/ml (solid blue diamonds), 10 μg/ml (solid red circles), or 100 μg/ml (solid green circles) paracetamol overnight at 4°C,
followed by analysis of viral inhibition in a type-1 assay. (B) Febrile Wistar rats were mock-treated (empty red circles), or treated with paracetamol (solid blue
circles),Cipa extract (empty green squares) or a combination of both (solid black squares), followed by monitoring of rectal temperature for 3 hours post-
treatment at regular intervals. Rectal temperatures between the control (mock-treated) and treatment groups were compared using one-way ANOVA
followed by Dunnett’s multiple comparison test (the single and double stars indicate significant differences in the treatment groups with respect to the control
group, corresponding to p values of0.05 and0.01, respectively).
doi:10.1371/journal.pntd.0004255.g005
Fig 6. Effect of Cipa extract on platelets. (A) Freshly collected human blood was incubated with saline (white bars) or Cipa extract (at 2 μg/ml: blue bars; or
10 μg/ml: red bars) for up to 4 hours. Aliquots were drawn at the indicated times for determination of platelet counts. (B) Wistar rats were orally administered
0.25%methyl cellulose containing Cipa extract ranging from 0–1000 mg/Kg body weight. Fresh blood collected from these rats at 0 (white bars), 1 (blue bars)
and 4 (red bars) hours post-administration, were analysed for platelet counts. For both panels, data shown are mean values (n = 5); the vertical bars
represent standard deviation, SD.
doi:10.1371/journal.pntd.0004255.g006
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also evaluated in an in vivo experiment using Wistar rats. In this experiment, platelet counts
were determined in blood drawn from rats which had been given Cipa extract orally. The
results presented in Fig 6B show that up to 4 hours post-treatment, Cipa extract (up to
1000 mg/kg body weight), did not affect platelet counts significantly (p>0.05 at the highest
dose of Cipa extract treatment for 4 hours).
The effect of Cipa extract on erythrocytes was also assessed, both in ex vivo and in vivo
assays, as done for platelets above. Incubation of freshly collected human erythrocytes with
Cipa extract at concentrations up to 400 μg/L did not cause discernible haemolysis (Fig 7A).
The blood samples, withdrawn from the Wistar rats (given Cipa extract, described above),
were also analysed for erythrocyte cell counts. This analysis, once again revealed that Cipa
extract (at concentrations as high as 1000 mg/kg body weight), did not affect erythrocyte
counts in the blood of Wistar rats up to 4 hours post-administration (Fig 7B). The difference
in erythrocyte counts between the treated and untreated rats was not statistically significant
(p>0.05). We also analysed total leucocyte and differential counts in the blood of Cipa-
treated Wistar rats (described in Figs 6B and 7B) and found no significant difference (S3
Fig).
A hallmark of severe dengue disease is the elevation of inflammatory cytokines which are
implicated in triggering events that culminate in vascular permeability and haemorrhage [2, 4].
To test if Cipa extract had any effect on the secretion of inflammatory cytokines, PBMCs were
isolated from blood and incubated with LPS to induce cytokine release. These cells were then
treated with Cipa extract and the release of pro-inflammatory cytokines monitored using com-
mercial ELISA kits. This experiment showed that the secretion of TNF-α and IL-1β was effi-
ciently suppressed by Cipa extract with IC50 values of 6.1±1.3 and 5.7±2.7 μg/ml, respectively.
An MTT assay showed that at these concentrations, Cipa extract has no discernible cytotoxicity
in both cell lines tested (CC50 = 78.9μg/ml in HepG2;>200μg/ml in LLCMK2). These data sug-
gest that Cipa extract possesses anti-inflammatory activity in addition to the antipyretic activity
documented in the experiment above.
Fig 7. Effect of Cipa extract on RBCs. (A) Erythrocytes from freshly collected human blood were incubated for 1 hour at 37°C, with varying concentrations
of Cipa extract (0–400 μg/ml), followed by measurement of haemolysis at 576 nm. TX-100 represents a control in which an equivalent aliquot of erythrocytes
were treated with Triton X-100 to achieve complete lysis. (B) Fresh blood collected from the Cipa extract-treated Wistar rats (described in Fig 5B) at 0 (white
bars), 1 (blue bars) and 4 (red bars) hours post-administration, were analysed for RBC counts. Data shown are mean values (n = 5); the vertical bars
represent SD.
doi:10.1371/journal.pntd.0004255.g007
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Preliminary toxicological evaluation
An exploratory toxicological study to assess any adverse effect of repeat dosing over a 1 week
span with Cipa extract was carried out in Wistar rats. Multiple physiological, haematological,
biochemical and clinical parameters were monitored. The results showed that animals treated
with up to 2000mg/kg body weight did not manifest any significant changes in any of these
parameters compared to vehicle-treated controls (S1–S4 Tables). This essentially corroborates
an earlier report that the Cipa extract is essentially non-toxic and well tolerated in the animal
model [29].
Discussion
In the absence of a licensed vaccine or antiviral drug, dengue continues to be a significant
global public health problem [3, 4]. This is further accentuated in India by its dense human
population which represents ~50% of the global population, estimated by WHO to be at risk of
dengue. Recently, indigenous diagnostic tests for the early detection of dengue have become
available in India [30]. The utility of early detection would be in being able to provide timely
antiviral therapy. Further, in the absence of a vaccine, administering antivirals when an out-
break is detected would offer a way of limiting disease spread. While the level of viremia is gen-
erally lower in DF, it increases by an order or two in magnitude in DHF/DSS [5, 6]. This
observation has led drug developers to hypothesize that lowering viremia by 1–2 logs may be
associated with a favourable prognosis [14].
As many of the modern drugs have been derived from natural precursors [17, 18], it is
increasingly being regarded that ethnopharmacology and traditional medicines offer an attrac-
tive option for identifying starting material for drug discovery initiatives [19, 31]. This pro-
vided the basis for the current work which was undertaken to explore the indigenous herbal
bio-resource in India to identify plants that may possess anti-DENV inhibitory activity.
Ayurveda represents a distinct discipline in Indian ethnomedicine and has provided a large
number of lead molecules for a variety of indications [19]. To provide a rational basis for plant
selection, the ayurvedic literature was examined for instances of illnesses with symptoms simi-
lar to dengue. Indigenous plants and herbs prescribed for treating these illnesses were chosen
for anti-DENV activity screening. In addition plants documented in the literature to possess
antiviral activity were also included. As each of the four DENV serotypes can cause severe den-
gue disease and all of these co-circulate in the hyper-endemic countries, it was considered
desirable for a drug to be effective against all the four serotypes. For this purpose a whole cell-
based bioassay-guided screening protocol was developed. In principle, an effective antiviral
drug could target extracellular virus and block its entry into susceptible cells or act on the virus
that has gained entry into cells by targeting one of the post-entry steps in the viral life cycle.
Assays were designed to identify herbal extracts targeting both extracellular and intracellular
virus. This resulted in the identification of Cipa extract and the extract from Phyllanthus
amarus as possessing pan-DENV inhibitory activity. As the finding of antiviral activity associ-
ated with Cipa (SI>45) was a novel one, further work focused on it. Its ability to inhibit DENV
in a time and dose-dependent manner in the type-1 assay format suggested that the Cipa
extract possesses a virucidal effect. Further, it was effective as an inhibitor over a ten-fold range
of DENV titers suggesting its potential to counteract high viremia. Consistent with this, an
analysis of the effect of Cipa extract on virus titers demonstrated a>1 log reduction compared
to untreated virus controls suggesting its potential utility in altering the course of severe dengue
disease to a more favourable outcome. Importantly, Cipa extract manifested statistically signifi-
cant protective efficacy in the AG129 mouse model [21, 27], which has emerged recently as the
only promising small animal model for in vivo DENV inhibitor testing [28].
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At this juncture, two options in terms of future course of development could be envisaged.
One, the Cipa extract could facilitate the drug discovery process. Two, the Cipa extract could
be the starting point for developing a carefully standardized herbal formulation for human use.
The former option would entail a systematic fractionation to isolate and characterize the active
ingredient which may provide small molecule drug lead(s) for optimization and further devel-
opment. This is both expensive and time-consuming. Additionally, there is the attendant possi-
bility of loss of activity upon fractionation to isolate pure compounds. Considering that Cipa is
in use for treating human ailments in Ayurvedic medicine in India [32, 33] and in traditional
medicine in several countries in South America [34], pursuing the latter option could be a lot
simpler and affordable, and of practical utility, particularly in the context of the resource-poor
dengue-endemic countries. Preliminary in vitro and in vivo experiments addressing the clinical
relevance of Cipa extract support the feasibility of pursuing the second option. For example the
drug paracetamol used commonly to treat dengue patients, does not affect the antiviral efficacy
of Cipa extract. Interestingly, Cipa extract appeared to possess an intrinsic antipyretic activity
which could synergize with that of paracetamol in the Wistar rat model. It also possessed the
ability to down-regulate the secretion of pro-inflammatory cytokines, particularly TNF- α
implicated in the pathogenesis of severe disease [2]. Further, Cipa extract did not have any dis-
cernible effect on platelet counts or on erythrocyte viability. Importantly, the extract was not
associated with any adverse toxicology. Finally, another factor in favour of the second option is
that, Cipa plant is available in several parts of the country and extracts prepared using plants
from different geographical locations are fairly similar in terms of their gross overall composi-
tion. This suggests that availability is not an issue and extract preparation can be reproducible.
In conclusion, Ayurveda knowledge-based selection of medicinal plants in conjunction with
a bioassay-guided screening protocol has resulted in the identification of Cipa extract which
manifests potent antiviral activity against all four prevalent DENV serotypes. In addition, this
extract also manifested dose-dependent protective efficacy in an in vivomodel, and appeared
to be compatible with future clinical use. The outcome of these studies should hopefully pave
the way to carry out a systematic development of Cipa extract to enable filing of an investiga-
tional new drug application with the Drug Controller General of India. Parts of this work have
been the subject of patent applications, several of which have been granted [35, 36].
Supporting Information
S1 Fig. Liquid chromatography/mass spectrometry profiles of Cipa extracts.Methanolic
extracts prepared from Cipa plants obtained fromMadhya Pradesh (upper panel) and South
India (lower panel) were analysed by LC/MS. Each peak is identified by molecular mass (lower
number) and retention time (upper number).
(TIF)
S2 Fig. Healthy and DENV-2-infected AG129 mice. Panel ‘a’ shows a pair of healthy AG129
mice. Panels ‘b’ and ‘c’ show DENV-2 infected mice manifesting ruffled fur, hunched back and
hind limb paralysis.
(TIF)
S3 Fig. Total and differential leukocyte counts in Cipa-treated Wistar rat blood. (A) Wistar
rats were orally administered 0.25% methyl cellulose containing Cipa extract ranging from
0–1000 mg/Kg body weight. Fresh blood collected from these rats at 0 (white bars), 1 (blue
bars) and 4 (red bars) hours post-administration, were analysed for total leukocyte counts. (B)
Blood samples collected from the different groups of Wistar rats described in panel in ‘A’ (vehi-
cle group: white bars; 100 mg Cipa group: blue bars; 300 mg Cipa group: red bars; 1000mg
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Cipa group: green bars) at the 0 hour time point were analysed for relative proportions of the
different leukocytes, presented as percent differential count with respect to the different cell
populations (Lym: lymphocytes; Neu: neutrophils; Mon: monocytes; Eos: eosinophils; Bas:
basophils; LUC: large unstained cells). (C) Similar data corresponding to those shown in panel
B, but generated using the 1 hour blood samples of panel ‘A’. (D) Similar data corresponding
to those shown in panel B, but generated using the 4 hour blood samples of panel ‘A’. For all
panels, data shown are mean values (n = 5); the vertical bars represent SD.
(TIF)
S1 Table. Mean body weight and food intake of Wistar rats treated with Cipa extract.
(DOCX)
S2 Table. Hematology parameters in Cipa extract-treated Wistar rats.
(DOCX)
S3 Table. Biochemical parameters in Cipa extract-treated Wistar rat sera.
(DOCX)
S4 Table. Organ weights in Cipa extract-treated Wistar rats.
(DOCX)
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